



An Independent Licensee of the Blue Cross and Blue Shield Association.

## Dry Needling of Myofascial Trigger Points Corporate Medical Policy

File Name: Dry Needling of Myofascial Trigger Points

File Code: 2.01.VT100

Origination: 04/2015

Last Review: 05/2021

Next Review: 05/2022

Effective Date: 07/01/2021

### Description/Summary

Trigger points are discrete, focal, hyperirritable spots within a taut band of skeletal muscle fibers that produce local and/or referred pain when stimulated. Dry needling refers to a procedure whereby a fine needle is inserted into the trigger point to induce a twitch response and relieve the pain.

For individuals who have trigger points associated with myofascial pain who receive dry needling of trigger points, the evidence includes a number of randomized controlled trials and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Overall, dry needling of trigger points has not been shown to be clinically superior to sham treatment or manual therapy. In addition, dry needling is associated with a high incidence of mild adverse events. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have myofascial trigger points associated with plantar heel pain who receive dry needling of trigger points, the evidence includes RCTs, quasi-experimental studies, and a systematic review. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The systematic review, which included 3 quasi-experimental studies, rated study quality as poor. One RCT was double-blinded and sham-controlled; it found a statistically significant greater reduction in pain in the dry needling group than in the sham group, but the difference was not clinically significant (ie, it did not meet the prespecified minimally important difference). The other RCT, a single-blind trial comparing dry needling with usual care, found a significantly greater reduction in pain at the end of active treatment, but not at follow-up 1 month later. Moreover, range of motion outcomes did not differ significantly between groups at either time point. To date, the studies have not demonstrated a statistical or a clinical benefit for dry needling.

Additional RCTs, especially those with a sham-control group, would strengthen the evidence

base. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have myofascial trigger points associated with temporomandibular myofascial pain who receive dry needling of trigger points, the evidence includes 1 RCT.

Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment - related morbidity. One double-blind, sham-controlled randomized trial was identified; it found that, 1 week after completing the intervention, there were no statistically significant differences between groups in pain scores or function (unassisted jaw opening without pain). There was a significantly higher pain pressure threshold in the treatment group. Additional RCTs, especially those with a sham-control group, are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

## Policy

Dry needling of trigger points for the treatment of myofascial pain is considered **investigational**.

### Coding Information

[Click the links below for attachments, coding tables & instructions.](#)

[Attachment I - CPT® Code Table & Instructions](#)

BCBSVT does not consider dry needling to be a manual therapy and should not be billed with CPT® code 97140 (Manual therapy techniques, (eg, mobilization/manipulation, manual lymph drainage, manual traction, one or more regions, each 15 minutes).

BCBSVT does not consider dry needling to be an injection and should not be billed with CPT® code 20552 (Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s) or CPT® 20553 (single or multiple trigger point(s), 3 or more muscles).

Note: because dry needling is not acupuncture, CPT® codes 97810-97814 are not appropriate.

### Reference Resources

1. Blue Cross and Blue Shield Association MPRM 2.01.100 - Dry Needling of Myofascial Trigger Points for Myofascial Pain. Last Reviewed: May 2021. Accessed May 2021.

### Document Precedence

Blue Cross and Blue Shield of Vermont (BCBSVT) Medical Policies are developed to provide clinical guidance and are based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. The applicable group/individual contract and member certificate language, or employer's benefit plan if an ASO group, determines benefits that are in effect at the time of service. Since medical practices and knowledge are constantly evolving, BCBSVT reserves the right to review and revise its medical policies periodically. To the extent that there may be any conflict between

medical policy and contract/employer benefit plan language, the member’s contract/employer benefit plan language takes precedence.

**Audit Information**

BCBSVT reserves the right to conduct audits on any provider and/or facility to ensure compliance with the guidelines stated in the medical policy. If an audit identifies instances of non-compliance with this medical policy, BCBSVT reserves the right to recoup all non-compliant payments.

**Administrative and Contractual Guidance**

**Benefit Determination Guidance**

NEHP/ABNE members may have different benefits for services listed in this policy. To confirm benefits, please contact the customer service department at the member’s health plan.

Federal Employee Program (FEP): Members may have different benefits that apply. For further information please contact FEP customer service or refer to the FEP Service Benefit Plan Brochure. It is important to verify the member’s benefits prior to providing the service to determine if benefits are available or if there is a specific exclusion in the member’s benefit.

Coverage varies according to the member’s group or individual contract. Not all groups are required to follow the Vermont legislative mandates. Member Contract language takes precedence over medical policy when there is a conflict.

If the member receives benefits through an Administrative Services Only (ASO) group, benefits may vary or not apply. To verify benefit information, please refer to the member’s employer benefit plan documents or contact the customer service department. Language in the employer benefit plan documents takes precedence over medical policy when there is a conflict.

**Policy Implementation/Update information**

04/2015	New Policy
07/2016	Revised to align with BCBSA Medical Policy
08/2017	Policy updated with literature review through February 23, 2017, reference 5-8 and 12 added. Policy statement unchanged to align with BCBSA MPRM 2.01.100.
09/2018	Policy statement unchanged to align with BCBSA MPRM 2.01.100.
09/2019	BCBSA Policy Reviewed. References Reviewed. Policy statement unchanged. Updated provider type in policy statement and coding instructions.

01/2020	Adaptive Maintenance Changes: 20560, 20561 considered Investigational. Removed codes 20999 & 97799, have providers use more specific codes 20560, 20561.
05/2021	Policy reviewed. No change to policy statement.

### Eligible providers

Qualified healthcare professionals practicing within the scope of their license(s).

### Approved by BCBSVT Medical Directors    Date Approved

Joshua Plavin, MD, MPH, MBA  
Chief Medical Officer

Kate McIntosh, MD, MBA, FAAP  
Senior Medical Director

### Attachment I CPT® Code Table & Instructions

Code Type	Number	Brief Description	Policy Instructions
CPT®	20560	Needle insertion(s) without injection(s); 1 or 2 muscle(s)	Deny Investigational
CPT®	20561	Needle insertion(s) without injection(s); 3 or more muscles	Deny Investigational